4//SEC Filing
Scadden David 4
Accession 0001439222-25-000108
CIK 0001439222other
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 4:18 PM ET
Size
8.3 KB
Accession
0001439222-25-000108
Insider Transaction Report
Form 4
Scadden David
Director
Transactions
- Exercise/Conversion
Common stock
2025-10-08$18.09/sh+200$3,618→ 17,803 total - Exercise/Conversion
Stock options (right to buy)
2025-10-08−200→ 27,107 totalExercise: $18.09Exp: 2032-06-21→ Common stock (200 underlying) - Sale
Common stock
2025-10-08$41.00/sh−200$8,200→ 17,603 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001707715
Filing Metadata
- Form type
- 4
- Filed
- Oct 9, 8:00 PM ET
- Accepted
- Oct 10, 4:18 PM ET
- Size
- 8.3 KB